|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,946 GBX | +0.29% |
|
-1.07% | +3.26% |
| Apr. 17 | AstraZeneca: presents new data at ECCMID | CF |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
Sept 9 (Reuters) - AstraZeneca PLC:
* ASTRAZENECA SAYS VOLUNTARILY PAUSED VACCINATION OF ITS COVID-19 EXPERIMENTAL SHOT TO ALLOW REVIEW OF SAFETY DATA BY AN INDEPENDENT COMMITTEE
* ASTRAZENECA SAYS THIS IS A ROUTINE ACTION WHICH HAS TO HAPPEN WHENEVER THERE IS A POTENTIALLY UNEXPLAINED ILLNESS IN ONE OF THE TRIALS
* ASTRAZENECA SAYS WORKING TO EXPEDITE THE REVIEW OF THE SINGLE EVENT TO MINIMIZE ANY POTENTIAL IMPACT ON THE TRIAL TIMELINE Further company coverage: (Reporting By Deena Beasley)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.26% | 211B | |
| +25.49% | 672B | |
| +24.08% | 550B | |
| -6.07% | 351B | |
| +15.28% | 317B | |
| +7.28% | 292B | |
| +0.78% | 203B | |
| -10.40% | 144B | |
| -7.06% | 141B | |
| -3.20% | 113B |
ASTRAZENECA PLC 
